# SOPHiA GENETICS SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SOPHiA GENETICS SA). ## Overview SOPHiA GENETICS SA is a Switzerland-based healthcare technology company that provides a cloud-native data analytics platform for interpreting complex medical and genomic datasets. Its core offering, SOPHiA DDM, is used by hospitals, cancer centers, laboratories, and life sciences organizations to standardize, analyze, and generate insights from diagnostic and research data. ## Products & services • SOPHiA DDM cloud analytics platform • Multimodal diagnostic data analysis • Genomic and biomarker interpretation applications • Clinical workflow decision-support tools • Life sciences and research data analytics - **SOPHiA DDM Platform** (70%) — Cloud-native software for standardizing and analyzing complex healthcare data. - **Clinical Applications** (20%) — Specific diagnostic applications used by hospitals and laboratories for patient testing. - **BioPharma Solutions** (10%) — Data analytics and testing services used by life sciences and biopharma partners. - SOPHiA DDM cloud analytics platform - Multimodal diagnostic data analysis - Genomic and biomarker interpretation applications - Clinical workflow decision-support tools - Life sciences and research data analytics ## Customers The company sells primarily to healthcare institutions that need software and analytics to interpret genomic and other diagnostic data in routine care. It also serves research and life sciences customers that use the platform for assay development, data analysis, and biomarker-related workflows. Customer value comes from faster interpretation, standardized analysis across sites, and the ability to expand usage across additional applications over time. - **Cancer centers** (primary) — Buy oncology-focused analytics and testing applications to support cancer diagnosis and treatment decisions. - **Hospitals and laboratories** (primary) — Use the platform to analyze patient samples and standardize diagnostic workflows across sites. - **Life sciences and biopharma** (secondary) — Purchase data analytics and research applications for biomarker and assay workflows. - **Reference laboratories** (primary) — Adopt modular applications to expand test menus and improve throughput and interpretation. - Cancer centers using SOPHiA DDM for oncology testing - Hospitals and laboratories standardizing diagnostic workflows - Life sciences and biopharma customers for research analytics - Clinical customers expanding from one assay to multiple applications - Large reference centers seeking consistent data interpretation ## Geography The company is headquartered in Rolle, Switzerland, and operates through subsidiaries in the U.S., France, the U.K., Brazil, Australia, Italy, and Germany. Its commercial footprint is international, with the U.S. highlighted as a major market and a key driver of customer expansion and platform adoption. - Headquartered in Rolle, Switzerland - Subsidiaries in the U.S., France, U.K., Brazil, Australia, Italy, Germany - U.S. is a major market for customer growth and usage expansion - Business is international, serving healthcare systems across regions - Geographic mix matters because healthcare buying is local and regulated ## Strategy The company’s strategy centers on expanding usage within existing customers and adding new clinical applications to the SOPHiA DDM platform. It is also building a broader installed base in large healthcare institutions and expanding its reach in the U.S. and other international markets, which supports a land-and-expand model. - **Expand within existing accounts** (short-term) — Usage growth across customers increases platform stickiness and raises account value without relying only on new logos. - **Broaden the application portfolio** (medium-term) — A wider menu of clinical and research applications improves relevance across more disease areas and testing workflows. - **Deepen U.S. market penetration** (medium-term) — The U.S. offers a large addressable market of reference centers and hospitals that can accelerate platform adoption. - Expand usage within existing customer accounts - Add new applications to broaden the platform menu - Grow in large U.S. cancer centers and hospitals - Strengthen land-and-expand commercial execution - Increase adoption across clinical and research workflows ## Risks The business depends on continued adoption by hospitals, laboratories, and research customers, so sales cycles, customer concentration, and renewal/expansion risk can affect growth. Because the company is tied to healthcare data analytics, it also faces regulatory, reimbursement, clinical validation, and competition risks, along with execution risk in scaling new applications and geographies. - **Dependence on account expansion** [high] — The platform model relies on customers adding applications over time; slower expansion would reduce growth and retention economics. - **Healthcare regulation and validation** [high] — Diagnostic software and clinical applications must meet regulatory, quality, and evidence requirements in each market. - **Customer concentration in key centers** [medium] — Large flagship customers can influence revenue momentum and reference value, creating concentration risk. - **Competitive pressure** [medium] — The company competes with other clinical data analytics, sequencing, and diagnostics vendors for institutional workflows. - Customer expansion depends on continued platform usage and adoption - Healthcare sales cycles can be long and procurement-driven - Regulatory and clinical-validation requirements can slow commercialization - Competition from other diagnostics and analytics platforms - International operations expose the business to local market and compliance risk ## Accounting Revenue recognition is a key judgment area because the platform mixes software access, diagnostics-related services, and customer-specific arrangements that may be recognized over time or at a point in time depending on the contract. Capitalized internal development costs, share-based compensation, and pension liabilities also require estimates that can materially affect reported results and asset values. - **Revenue recognition** — Can shift revenue between periods - **Capitalized development costs** — Affects operating expense and asset balances - **Share-based compensation** — Impacts operating costs and dilution - **Defined benefit pension estimates** — Affects OCI and balance sheet liabilities - Revenue recognition depends on contract structure and delivery obligations - Capitalized internal development costs affect intangible asset balances - Share-based compensation impacts operating expense and equity dilution - Defined benefit pension assumptions affect liabilities and remeasurement - Interim tax and pension estimates can move quarterly results --- *Last updated: 2026-09-28T12:13:57.988200+00:00*